Corvus Pharmaceuticals, INC 8-K filings

Corvus Pharmaceuticals provided a business update and reported second quarter 2026 financial results, highlighting progress in soquelitinib trials and a strong cash position extending runway into mid-2028.

Corvus Pharmaceuticals announces the resignation of director Ian T. Clark, effective July 22, 2026, after nine years of service.

Corvus Pharmaceuticals stockholders re-elected directors, ratified auditors, and approved executive compensation at the 2026 Annual Meeting.

Corvus Pharmaceuticals announced positive final data from a Phase 1 trial of soquelitinib for atopic dermatitis, showing safety, efficacy, and potential for durable, drug-free remissions.

Corvus Pharmaceuticals reported first quarter 2026 financial results, highlighting positive Phase 1 data for soquelitinib in atopic dermatitis and a strengthened cash position following a January financing.

Corvus Pharmaceuticals appoints Dr. Andrew C. Chan to its Board of Directors as Scott Morrison resigns.

Corvus Pharmaceuticals, Inc. amended its at-the-market sales agreement with Jefferies LLC, increasing the potential aggregate offering price for common stock sales to $200 million.

Corvus Pharmaceuticals announced its fourth quarter and full year 2025 financial results, alongside positive clinical data for soquelitinib in atopic dermatitis and progress in its PTCL and other immune disease programs, bolstered by a recent $189 million financing.

Corvus Pharmaceuticals, Inc. successfully completed an underwritten public offering of 9,085,778 shares of common stock, including the full exercise of the underwriters' option, generating approximately $188.3 million in net proceeds.

Corvus Pharmaceuticals has suspended its planned $100 million common stock offering, with no shares sold prior to the halt.

Corvus Pharmaceuticals announced positive Phase 1 clinical trial results for soquelitinib in moderate to severe atopic dermatitis, showing favorable safety and efficacy and plans for a Phase 2 trial.

Corvus Pharmaceuticals provided a business update and reported third-quarter 2025 financial results, highlighting progress in its soquelitinib clinical programs for atopic dermatitis and T cell lymphoma.

Corvus Pharmaceuticals, Inc. announced the appointment of David Moore as a Class III director to its Board, effective October 2, 2025, also assigning him to the Compensation and Nominating Committees.

Corvus Pharmaceuticals announced positive Phase 1 clinical trial data for soquelitinib in atopic dermatitis, progress across its pipeline, and an extended cash runway into Q4 2026 following warrant exercises.

Corvus Pharmaceuticals, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all three proposals, including director elections, auditor ratification, and executive compensation, were approved.

Corvus Pharmaceuticals announced positive interim results from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, demonstrating favorable safety and efficacy, and has initiated an extension cohort.

Corvus Pharmaceuticals reports encouraging interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis and provides a business update alongside its first quarter 2025 financial results.

Corvus Pharmaceuticals appoints Richard van den Broek to its Board of Directors, effective April 8, 2025, with roles on the Audit and Nominating Committees.

Corvus Pharmaceuticals announced a business update and its financial results for Q4 and the full year 2024, highlighting progress with soquelitinib and other clinical programs.

Corvus Pharmaceuticals reports encouraging interim results from a Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing significant improvements compared to placebo.

Corvus Pharmaceuticals reports promising interim results from a Phase 1 trial of soquelitinib for atopic dermatitis, showing significant improvement in patients, and secures $12.7 million through warrant exercises.

Corvus Pharmaceuticals announced its third quarter 2024 financial results, provided a business update, and highlighted progress in its clinical trials for soquelitinib.

Corvus Pharmaceuticals has entered into a sub-sublease agreement for approximately 20,916 square feet of office space in South San Francisco, commencing no later than February 1, 2025.

Corvus Pharmaceuticals announced encouraging early results from its atopic dermatitis trial and progress in its T-cell lymphoma program, alongside its second quarter 2024 financial results.

Corvus Pharmaceuticals held its 2024 Annual Meeting of Stockholders, where a director was elected, the accounting firm was ratified, and executive compensation was approved on an advisory basis.

Corvus Pharmaceuticals has entered into a securities purchase agreement to raise approximately $30.2 million through a registered direct offering of common stock and warrants.

Corvus Pharmaceuticals announced encouraging clinical trial results for its drug candidates and a successful $30.6 million financing round.

Corvus Pharmaceuticals has amended its sales agreement with Jefferies LLC, reducing the aggregate offering price of its at-the-market program to $8.2 million.

Corvus Pharmaceuticals is progressing its lead drug, soquelitinib, towards a Phase 3 trial for T-cell lymphoma and a Phase 1 trial for atopic dermatitis, while reporting its 2023 financial results.

Corvus Pharmaceuticals announces the passing of board member Edith P. Mitchell, M.D., a distinguished figure in healthcare and oncology.